Multivariate analysis of nonrelapse mortality, relapse, treatment failure, and overall mortality
| . | HR (95% CI) . | P . | |
|---|---|---|---|
| Nonrelapse mortality | T cell–replete | 1.00 | |
| ATG | 1.12 (0.81-1.55) | .50 | |
| Alemtuzumab | 0.85 (0.57-1.26) | .42 | |
| Relapse | T cell–replete | 1.00 | |
| ATG | 1.02 (0.74-1.42) | .89 | |
| Alemtuzumab | 0.85 (0.57-1.27) | .43 | |
| Treatment failure | T cell–replete | 1.00 | |
| ATG | 1.08 (0.86-1.36) | .53 | |
| Alemtuzumab | 0.92 (0.69-1.22) | .56 | |
| Overall mortality | T cell–replete | 1.00 | |
| ATG | 1.07 (0.84-1.37) | .58 | |
| Alemtuzumab | 0.83 (0.62-1.11) | .20 | |
| . | HR (95% CI) . | P . | |
|---|---|---|---|
| Nonrelapse mortality | T cell–replete | 1.00 | |
| ATG | 1.12 (0.81-1.55) | .50 | |
| Alemtuzumab | 0.85 (0.57-1.26) | .42 | |
| Relapse | T cell–replete | 1.00 | |
| ATG | 1.02 (0.74-1.42) | .89 | |
| Alemtuzumab | 0.85 (0.57-1.27) | .43 | |
| Treatment failure | T cell–replete | 1.00 | |
| ATG | 1.08 (0.86-1.36) | .53 | |
| Alemtuzumab | 0.92 (0.69-1.22) | .56 | |
| Overall mortality | T cell–replete | 1.00 | |
| ATG | 1.07 (0.84-1.37) | .58 | |
| Alemtuzumab | 0.83 (0.62-1.11) | .20 | |